Oruka Therapeutics (ORKA) vs Recursion Pharmaceuticals (RXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Oruka Therapeutics (ORKA) has outperformed Recursion Pharmaceuticals (RXRX) over the past year, gaining 221.4% versus a loss of 26.2%. Over five years, ORKA leads with a +145.3% price change compared with -77.1% for RXRX. Oruka Therapeutics is the larger company by market cap ($5.44 billion vs $2.34 billion), about 2.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ORKA | RXRX |
|---|---|---|
| Share price | $82.11 | $4.36 |
| Market cap | $5.44B | $2.34B |
| 1-day change | +6.25% | +10.38% |
| YTD return | +170.90% | +6.60% |
| 1-year return | +221.37% | -26.23% |
| 5-year return | +145.25% | -77.10% |
| EPS (TTM) | $-2.04 | $-1.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $74.68M |
| Revenue growth (YoY) | — | +26.92% |
| Net income (latest FY) | $-105.43M | $-644.76M |
| Gross margin | — | 4.99% |
| Operating margin | — | -867.87% |
| Net margin | — | -863.35% |
| 52-week high | $115.52 | $7.18 |
| 52-week low | $24.46 | $2.77 |
| Distance from 52-week high | -28.92% | -39.28% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +88.77% | +65.60% |
| Average volume | 902.84K | 20.70M |
| Shares outstanding | 66.21M | 535.34M |
| Employees | 68 | 600 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Oruka Therapeutics is about 2.3 times larger than Recursion Pharmaceuticals by market value ($5.44B vs $2.34B).
- ORKA has outperformed RXRX by 247.6 percentage points over the past year.
About Oruka Therapeutics
ORKA stock →Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.
Healthcare · Biotechnology · 68 employees
About Recursion Pharmaceuticals
RXRX stock →Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Healthcare · Biotechnology · 600 employees
ORKA vs RXRX FAQ
Which is bigger, Oruka Therapeutics or Recursion Pharmaceuticals?
Oruka Therapeutics (ORKA) is larger, with a market capitalization of $5.44B compared with $2.34B for Recursion Pharmaceuticals (RXRX).
Which stock has performed better over the past year, ORKA or RXRX?
ORKA returned +221.37% over the past 12 months, compared with -26.23% for RXRX (price return, excluding dividends). Past performance does not predict future results.
Are Oruka Therapeutics and Recursion Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.